Drugs / LONTUCIREV (REPLICATING ADENOVIRUS)
LONTUCIREV (REPLICATING ADENOVIRUS)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00006106 | Jul 1999 → ? | lip and oral cavity carcinoma, oropharynx cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LONTUCIREV (REPLICATING ADENOVIRUS) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108619 ↗ |
| Known as | CI-1042 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108619 ↗ |
| Known as | Lontucirev | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108619 ↗ |
| Known as | ONYX-015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006106 ↗ |
| Route | Other | “Patients receive intraarterial infusions of ONYX-015.” NCT00006106 ↗ |